Sildenafil citrate does not affect cardiac contractility in human or dog heart

References

• Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47–52
   PubMedGoogle Scholar
• Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998;159: 2164–71
   PubMed Web of Science ®Google Scholar
• Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999;274: 13729–32
   PubMed Web of Science ®Google Scholar
• Jeremy JY, Ballard SA, Naylor AM, Miller MAW, Angelini GD. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997;79: 958–63
   PubMedGoogle Scholar
• Moreland RB, Goldstein I, Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 1998;62: 309–18
   PubMed Web of Science ®Google Scholar
• Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151: 54–61
   PubMed Web of Science ®Google Scholar
• Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997;9: 123–6
   PubMed Web of Science ®Google Scholar
• Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair SN. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994;140: 930–7
   PubMed Web of Science ®Google Scholar
• Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra®) in clinical populations: an update. Urology 2002;60 (Suppl 2B):12–27
   PubMed Web of Science ®Google Scholar
• Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999;83:13C–20C
   PubMed Web of Science ®Google Scholar
• Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342: 1622–6
   PubMed Web of Science ®Google Scholar
• Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36: 845–51
   PubMed Web of Science ®Google Scholar
• Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002;287: 719–25
   PubMed Web of Science ®Google Scholar
• Fox KM, Thadani U, Ma PTS, et al. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J 2003; submitted
   Google Scholar
• Patrizi R, Leonardo F, Pelliccia F, et al. Effect of sildenafil citrate upon myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers. Ital Heart J 2001;2: 841–4
   PubMedGoogle Scholar
• Zusman RM, Prisant LM, Brown MJ. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. J Hypertens 2000;18: 1–5
   Web of Science ®Google Scholar
• Kloner RA. Cardiovascular safety profile for sildenafil. Sexual Dysfunction in Medicine 2000;1: 66–9
   Google Scholar
• Cheitlin MD, Hutter AM, Brindis RG, Ganz P, Kaul S, Russell RO, Zusman RM. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999;99: 168–77
   PubMed Web of Science ®Google Scholar
• DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panel. Am J Cardiol 2000;86: 175–81
   PubMed Web of Science ®Google Scholar
• Padma-Nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002;60(Suppl 2B):67–90
   PubMed Web of Science ®Google Scholar
• Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999;83:35C–44C
   PubMed Web of Science ®Google Scholar
• Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000;36: 25–31
   PubMed Web of Science ®Google Scholar
• Stief CG, Uckert S, Becker AJ, Harringer W, Truss MC, Forssmann WG, Jonas U. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology 2000;55: 146–50
   PubMed Web of Science ®Google Scholar
• Senzaki H, Smith CJ, Juang GJ, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 2001;15: 1718–26
   PubMed Web of Science ®Google Scholar
• Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002;56: 453–9
   PubMed Web of Science ®Google Scholar
• Corbin JD, Gettys TW, Blackmore PF, Beebe SJ, Francis SH, Glass DB, Redmon JB, Sheorain VS, Landiss LR. Purification and assay of cAMP, cGMP, and cyclic nucleotide analogs in cells treated with cyclic nucleotide analogs. Methods Enzymol 1988;159: 74–82
   PubMed Web of Science ®Google Scholar
• Gopal VK, Francis SH, Corbin JD. Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem 2001;268: 3304–12
   PubMedGoogle Scholar
• Sugden PH, Corbin JD. Adenosine 3’:5’-cyclic monophosphate-binding proteins in bovine and rat tissues. Biochem J 1976;159: 423–7
   PubMed Web of Science ®Google Scholar
• Corbin JD, Sugden PH, Lincoln TM, Keely SL. Compartmentalization of adenosine 3’:5’-monophosphate and adenosine 3’:5’-monophosphate-dependent protein kinase in heart tissue. J Biol Chem 1977;252: 3854–61
   PubMed Web of Science ®Google Scholar
• Gillies H, Roblin D, Jackson G. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol 2002;86: 131–41
   PubMed Web of Science ®Google Scholar
• Sugiyama A, Satoh Y, Shiina H, Takahara A, Yoneyama M, Hashimoto K. Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. J Cardiovasc Pharmacol 2001;38: 940–6
   PubMed Web of Science ®Google Scholar
• Parums DV, Charlton RG, Johnson N, Cindrove T, Skepper J, Phillips S, Ridden J, Burslem F. Immunohistochemical (IHC), in situ hybridisation (ISH) and biochemical characterisation of phosphodiesterase type 5 (PDE5) in normal and ischaemic human cardiac tissue (PDE5). Eur Heart J 2000;21: 616
   Web of Science ®Google Scholar
• Corbin JD, Francis SH, Osterloh IH. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue [letter]. Urology 2000;56: 545
   PubMed Web of Science ®Google Scholar